Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Borchmann

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Der Pathologe|December 22, 2005
[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]P Borchmann, K Behringer, A Josting, et al.
Leukemia & Lymphoma|August 26, 1998
Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphomaR Schnell, E Vitetta, J Schindler, et al.
Annals of Hematology|May 25, 2002
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemiaT Pfitzner, M Reiser, S Barth, et al.
Nuklearmedizin. Nuclear Medicine|February 26, 2003
[Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects]J O Staak, M Dietlein, A Engert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphomaP Borchmann, R Schnell, R Knippertz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2013
Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitionsB Klimm, H Goergen, M Fuchs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 studyD A Eichenauer, S Kreissl, I Bühnen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2010
No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study GroupK Behringer, L Wildt, H Mueller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphomaP J Bröckelmann, H Müller, O Casasnovas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18C-A Voltin, H Goergen, C Baues, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Der Pathologe|December 22, 2005
[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]P Borchmann, K Behringer, A Josting, et al.
Leukemia & Lymphoma|August 26, 1998
Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphomaR Schnell, E Vitetta, J Schindler, et al.
Annals of Hematology|May 25, 2002
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemiaT Pfitzner, M Reiser, S Barth, et al.
Nuklearmedizin. Nuclear Medicine|February 26, 2003
[Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects]J O Staak, M Dietlein, A Engert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphomaP Borchmann, R Schnell, R Knippertz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2013
Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitionsB Klimm, H Goergen, M Fuchs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 studyD A Eichenauer, S Kreissl, I Bühnen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2010
No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study GroupK Behringer, L Wildt, H Mueller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphomaP J Bröckelmann, H Müller, O Casasnovas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18C-A Voltin, H Goergen, C Baues, et al.
Pageof 5